The shifting landscape of commercialisation in 2026

By 2026, the global healthcare sector has moved away from volume-based models toward value-based care. This transition means providers are now reimbursed based on patient outcomes rather than the number of tests performed. Your GTM roadmap must reflect this by proving how your technology reduces long-term costs. Data interoperability has also become a mandatory requirement. Systems that cannot share data across the full value chain are being phased out in favour of integrated platforms. Current market conditions favour specialist healthtech companies that demonstrate capital efficiency, particularly as Australian healthtech investment continues to focus on proven clinical utility following the $856M+ invested in the sector in 2023.

Identifying your primary entry point

Your choice of entry point dictates your regulatory path and capital requirements. You must decide between a Direct-to-Consumer (DTC) model or a B2B2C approach through healthcare providers. While DTC offers faster user acquisition, the B2B2C model often provides more defensible strategic positioning through established referral networks. Many founders find success using a "Trojan Horse" strategy. This involves starting with administrative efficiency tools that solve immediate operational pain points. Once you have established trust and embedded your software into the daily routine of a clinic, you can expand into higher-value clinical decision support tools. Systemic integration is the successful alignment of clinical utility, financial reimbursement, and administrative workflow within a healthcare ecosystem. To learn more about how we evaluate these models, explore the Dreamoro thesis on the future of healthtech. Medicine 3.0 represents a fundamental shift from the reactive "sick care" of the 20th century to a proactive, data-driven model. It prioritises prevention, personalisation, and long-term healthspan. For your digital health go-to-market strategy, this isn't merely a clinical philosophy; it's a commercial framework. Startups adopting this lens target the 20% of patients who drive 80% of healthcare costs by intervening long before an acute event occurs. AI-enabled healthtech acts as the engine of this transition. It fundamentally alters the cost-to-serve. Traditionally, continuous patient monitoring required expensive, manual oversight. Now, algorithms process baseline data at scale, escalating only high-risk anomalies to clinicians. This efficiency allows you to scale your GTM model without a linear increase in clinical headcount. Medicine 3.0 startups gain a strategic advantage by attracting early adopters who value data sovereignty and proactive wellness, creating a high-engagement user base that traditional providers struggle to reach.

Prevention as a commercial value proposition

Selling prevention requires a shift in how you present value to payers. You must build a business case focused on long-term cost avoidance rather than immediate fee-for-service revenue. The primary hurdle is the time-to-value gap. While acute treatments show results in days, preventative measures may take years to yield a measurable return on investment. Successful founders bridge this by identifying high-risk cohorts where "near-miss" events are frequent and costly. You can find more detail on this shift in our analysis of Medicine 3.0 and its impact on the healthcare value chain.

AI-first product positioning

Your positioning must move beyond the "AI-powered" buzzword. Sophisticated buyers and clinicians look for clinical utility and evidence of navigating digital health regulation with rigour. Trust is built through transparent algorithms and datasets validated against gold-standard clinical benchmarks. When AI functions as a decision-support tool rather than a "black box," it reduces the friction of clinician onboarding. It transforms a complex integration into a seamless workflow enhancement that saves time rather than adding to the administrative burden. Building a defensible position in this space requires a deep understanding of how your technology fits into existing clinical pathways. If you are developing a solution that fits this paradigm, you may want to explore the Dreamoro investment thesis to see how we view the future of preventative care. Australia’s healthcare system is a bifurcated model that requires a dual-track approach. The public sector, funded by the federal government but operated by state health departments, manages acute care and public hospitals. In contrast, the private sector includes general practitioners, allied health professionals and private hospitals. Your digital health go-to-market strategy must account for this split. Selling to a public hospital in New South Wales involves different procurement cycles and compliance standards than targeting a private cardiology clinic in Queensland. National bodies like the Australian Digital Health Agency (ADHA) manage infrastructure, while state-based procurement remains decentralised; each state maintains its own tender processes and digital health standards.

Regulatory compliance as a strategic moat

The Therapeutic Goods Administration (TGA) classifies Software as a Medical Device (SaMD) based on the level of clinical risk. Founders often view TGA approval as a final hurdle, yet early engagement serves as a significant commercial advantage. It defines your clinical claims and creates a barrier to entry for less disciplined competitors. This rigorous approach aligns with the WHO's Global Strategy on Digital Health, which emphasises the necessity of robust regulatory frameworks to ensure patient safety. Data privacy is equally critical. You must ensure compliance with the Australian Privacy Act 1988 and design your platform for seamless My Health Record integration to maintain trust with clinical users. In 2026, maintaining ISO 13485 certification will be the baseline requirement for any founder seeking to integrate AI-driven diagnostics into clinical workflows.

Payer models in Australia

Securing a foothold in the Australian market requires understanding who pays for your solution. The Medicare Benefit Schedule (MBS) is the primary engine for reimbursement in the private sector. If your product does not align with existing MBS codes, you must build a case for direct payment from other sources. A successful digital health go-to-market strategy in Australia often targets these three payer groups: For a deeper understanding of how these entities interact, see our analysis of The Australian Healthtech Ecosystem. Mapping these relationships early allows you to align your product development with the specific procurement needs of the Australian market. Engineering is your most potent commercial weapon. A digital health go-to-market strategy fails when the product remains a closed island. Founders often mistake technical debt for a post-launch problem, yet in healthtech, it is a commercial blocker. If your platform doesn't speak FHIR or HL7 standards from the first deployment, your sales cycle will stall for 12 to 18 months while you build custom connectors for hospital legacy systems. To ensure your technical build supports rapid scaling, follow these five steps:

Product engineering as a GTM lever

Clinicians don't tolerate friction. A 2023 Medscape report highlighted that 42% of physicians experience burnout, with poor technology interfaces cited as a primary contributor. "Good enough" UX is a terminal failure in a clinical setting. Your interface must reduce cognitive load by anticipating a doctor's next move through intelligent design. This focus on usability is a core component of Mastering Your Healthtech Go-to-Market Strategy, ensuring that your product becomes a permanent part of the clinical workflow rather than a temporary burden.

The feedback loop: Engineering and sales

Sales teams often promise customisations to close deals, leading to the "feature creep" trap. This dilutes your value proposition and drains your capital. You need a formalised process where clinical feedback from the field reaches the dev team without distorting the product roadmap. Our Studio model facilitates this by integrating engineering with commercial strategy. This alignment ensures your dev team builds what the market demands, transforming engineering from a cost centre into a growth engine. By maintaining a tight loop, you can iterate on pilots in a 50-bed facility and apply those learnings to a 500-bed hospital system within the same quarter. Build a product that scales alongside your commercial ambitions. Partner with our Studio team to align your engineering roadmap. Execution is the primary point of failure for early stage founders. Capital alone cannot solve the technical debt or regulatory hurdles inherent in a digital health go-to-market strategy. Dreamoro operates on a "Two arms. One mission." model to bridge this gap. Dreamoro Ventures provides the necessary capital, while Dreamoro Studio serves as the engine for product delivery and commercialisation. This integrated platform allows founders to focus on clinical validation while we manage the technical execution. It's a partnership designed to reduce the friction of scaling in a highly regulated sector. Success in the 2026 market requires moving from pre-seed to Series A with a defensible strategic position. We provide managed dev ops to accelerate this transition by building high-performing, compliant infrastructure. Our approach is informed by deep market intelligence, including a comprehensive mapping of 1,005 healthtech companies. This data allows us to identify specific gaps in the Australian and global markets, ensuring your product architecture supports a scalable digital health go-to-market strategy from day one. We don't just invest; we build the technical foundations required for long-term viability.

Beyond capital: The role of a venture studio

Australian healthtech founders often lack access to operator-led support that goes beyond high-level advice. A venture studio provides a dedicated engineering team that understands healthcare data standards, FHIR protocols, and security requirements. For example, we recently accelerated a portfolio company's GTM timeline by 18 weeks through AI-first product engineering. By automating clinical documentation workflows, the founder moved from pilot stage to a paid commercial contract significantly faster than the 12-month industry average. You can learn more about our operational support via Dreamoro Studio.

Building the future of healthcare together

We're looking for founders building capital-efficient, AI-enabled solutions that address systemic inefficiencies. If you're developing Medicine 3.0 technologies, your focus should be on building a robust, evidence-based product. Dreamoro provides the strategy and commercialisation support to help you manage complex regulatory pathways and procurement cycles. Founders ready to review their GTM readiness can engage with us to discuss how our ecosystem can support their growth. The future of healthcare is being built now; we're here to back the architects who are making it a reality. Transitioning from Medicine 2.0 to Medicine 3.0 requires a fundamental shift in how founders approach their commercial roadmaps. Success in 2026 doesn't happen by accident; it hinges on aligning technical engineering with regulatory milestones early in the development cycle. It's not enough to build a functional product. Standing out in the Australian market, where Dreamoro has mapped 1,005 healthtech companies, requires a deep understanding of systemic complexity and a defensible digital health go-to-market strategy that addresses the specific needs of clinicians and payers. Scaling a venture within this ecosystem involves managing intricate regulatory pathways while maintaining capital efficiency. Bridging the gap between a pilot and a sustainable model remains a significant hurdle. Dreamoro Studio addresses this by providing an integrated venture capital and strategy studio model. With a specialist focus on AI-enabled healthtech, the studio provides the domain expertise required to commercialise complex innovations effectively. Partner with Dreamoro Studio to commercialise your healthtech organisation. The future of healthcare is being built by those who prioritise precision and strategic discipline today.

What is the most common mistake in a digital health go-to-market strategy?

The most common mistake is failing to identify the economic buyer versus the clinical user. Founders often build for doctors but forget that hospital procurement committees or private insurers hold the budget. This misalignment leads to high engagement but zero revenue. Your digital health go-to-market strategy must map the entire decision-making unit, including the IT security team and the clinical lead, before you commit significant capital to a specific channel.

How long does a typical healthtech sales cycle take in Australia?

A typical sales cycle in the Australian healthcare system ranges from 9 to 24 months depending on the sector. Public hospital procurement often exceeds 18 months due to tender requirements and state-based health department approvals. Private health insurers typically take 12 months to move from a pilot to a full commercial rollout. Founders should secure at least 24 months of runway to survive these timelines without compromising their equity position.

Do I need TGA approval before I start my GTM execution?

You don't need TGA approval to conduct market research or develop your strategy, but you must have it before commercial supply. If your product meets the definition of a medical device, such as diagnostic software, you cannot legally market or sell it without Australian Register of Therapeutic Goods inclusion. The TGA's 2024 guidance clarifies that even free trials can constitute supply in certain clinical contexts, so regulatory strategy must precede execution.

How do I price a digital health solution for the Australian market?

Pricing in Australia should be benchmarked against existing Medicare Benefits Schedule items or hospital Diagnosis Related Group costings. If your solution saves a hospital $1,500 per patient by reducing readmissions, price your license to capture a clear percentage of that saved value. Avoid US-style high-margin list prices, as Australian procurement focuses on total cost of ownership and budget impact rather than just clinical outcomes.

What is the difference between a user and a payer in healthtech GTM?

The user is the individual interacting with the software, while the payer is the entity responsible for the bill. In the Australian system, a GP might be the user of a remote monitoring tool, but the patient or the Department of Health is often the payer. Successful founders distinguish these roles early. If the payer doesn't see a clear health economic benefit, the user's enthusiasm won't result in a contract.

Can I use a US-based GTM strategy for the Australian healthcare system?

You cannot transplant a US-based strategy into the Australian system because the reimbursement structures are fundamentally different. The US relies heavily on private insurance and CPT codes, whereas Australia is a hybrid system dominated by the public sector and Medicare. A digital health go-to-market strategy built for American Value-Based Care will fail in a system where state-based budgets and federal funding pools operate under distinct regulatory silos.

What metrics should I track during a digital health pilot?

Track clinical efficacy, health economic impact, and workflow integration during any digital health pilot. Specifically, focus on the time to value for the clinician and the reduction in bed days or emergency department presentations for the hospital. Data from 2023 shows that pilots failing to demonstrate a clear 3:1 return on investment within six months rarely convert to long-term commercial contracts.

How does Medicine 3.0 affect my commercialisation plan?

Medicine 3.0 shifts your commercialisation plan from treating acute illness to managing long-term health and prevention. This requires a business model focused on continuous monitoring and data-driven insights rather than episodic interventions. Your framework must account for longer-term patient engagement and the collection of longitudinal data, which are the core requirements for the proactive, personalised healthcare models Dreamoro expects to dominate by 2026.

Back to BlogARTICLE

Digital Health Go-to-Market Strategy: A Founder’s Framework for 2026

Our founder's framework for a digital health go-to-market strategy helps you navigate Australia's complex system and secure recurring revenue by 2026.

Klaus Bartosch · 24 April 2026 · 16 min read

Frequently Asked Questions

Klaus Bartosch

CEO, Founder & Managing Partner